Alto Neuroscience
ANROAlto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through a precision medicine approach.
Earnings
Next report
Nov 11, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through a precision medicine approach. The company utilizes its proprietary Precision Psychiatry Platform to identify brain-based biomarkers, such as EEG and neurocognitive assessments, to match patients with personalized drug candidates. Their pipeline targets high-need therapeutic areas including major depressive disorder, bipolar depression, schizophrenia, and Parkinson’s disease.
A pioneer in precision psychiatry using brain-based biomarkers to disrupt the traditional all-comer approach to CNS drug development.
FAQ
- What is Alto Neuroscience's market cap?
- Alto Neuroscience (ANRO) has a market capitalization of $886.9M and trades on NYSE.
- Who are Alto Neuroscience's competitors?
- Alto Neuroscience's key competitors include Xenon Pharmaceuticals Inc, Minerva Neurosciences, Inc, Neumora Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Alto Neuroscience partner with?
- Alto Neuroscience's notable partners include Stanford University, Sanofi, Avalo Therapeutics, Inc., and others.
- Where is Alto Neuroscience headquartered?
- Alto Neuroscience is headquartered in United States of America and employs approximately 63 people. It has been publicly traded since 2024.